Suggestions
Press Release And News Distribution
News
Drug Launches & Approvals
Clinical Trials
Market Insights
Artificial Intelligence
Commercial
More
Reports
Infographics
Interviews & Opinions
Company Spotlights
Events
Contact
About
Company Spotlights
Search
Search
Recent Posts
FDA Approves Johnson & Johnson’s DARZALEX FASPRO (Daratumumab and Hyaluronidase-fihj) for High-Risk Smoldering Multiple Myeloma: Advancing Early Multiple Myeloma Intervention
FDA Approves AstraZeneca’s KOSELUGO (Selumetinib) for Adults with Neurofibromatosis Type 1 with Inoperable Plexiform Neurofibromas
FDA Approves Amgen’s IMDELLTRA (Tarlatamab-dlle): A Breakthrough in Extensive Stage Small Cell Lung Cancer Treatment
FDA Approves Merck’s KEYTRUDA and KEYTRUDA QLEX in Combination with Astellas Pharma’s PADCEV as Perioperative Treatment for Muscle-Invasive Bladder Cancer
Novartis Receives FDA Approval for ITVISMA Gene Replacement Therapy in Spinal Muscular Atrophy
Recent Comments
Hi There!
Eu qui dicat praesent iracundia, fierent partiendo referrentur ne est, ius ea falli dolor copiosae. Usu atqui veniam ea, his oportere facilisis suscipiantur ei. Qui in meliore conceptam, nam esse option eu. Oratio voluptatibus ex vel.
Banner
Latest Interviews
Newsletter
Authors
pharmaglobenews
Global AI in Medical Diagnostics Market Set for Exceptional Growth at a CAGR of ~22% by 2032 | DelveInsight
Rachel Hartley
FDA Approves Johnson & Johnson’s DARZALEX FASPRO (Daratumumab and Hyaluronidase-fihj) for High-Risk Smoldering Multiple Myeloma: Advancing Early Multiple Myeloma Intervention
News
Drug Launches & Approvals
Clinical Trials
Market Insights
Artificial Intelligence
Commercial
More
Reports
Infographics
Interviews & Opinions
Company Spotlights
Events
Contact
About
